Invesco
MIRM icon

Invesco’s Mirum Pharmaceuticals MIRM Stock Holding History

Invesco’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$160M Buy
1,364,084
+1,078,848
+378% +$108M 0.01% 759
2026
Q1 		$26.4M Buy
285,236
+220,285
+339% +$20.7M ﹤0.01% 1317
2025
Q4 		$5.13M Sell
64,951
-36,520
-36% -$2.62M ﹤0.01% 2235
2025
Q3 		$7.44M Buy
101,471
+36,818
+57% +$2.34M ﹤0.01% 2013
2025
Q2 		$3.29M Sell
64,653
-248,770
-79% -$11.1M ﹤0.01% 2384
2025
Q1 		$14.1M Buy
313,423
+14,144
+5% +$667K ﹤0.01% 1600
2024
Q4 		$12.4M Buy
299,279
+14,747
+5% +$615K ﹤0.01% 1725
2024
Q3 		$11.1M Buy
284,532
+487
+0.2% +$19.4K ﹤0.01% 1785
2024
Q2 		$9.71M Buy
284,045
+245,024
+628% +$6.42M ﹤0.01% 1808
2024
Q1 		$980K Sell
39,021
-45,846
-54% -$1.26M ﹤0.01% 2998
2023
Q4 		$2.51M Sell
84,867
-78,900
-48% -$2.39M ﹤0.01% 2532
2023
Q3 		$5.18M Buy
163,767
+128,374
+363% +$3.52M ﹤0.01% 2189
2023
Q2 		$916K Sell
35,393
-5,183
-13% -$138K ﹤0.01% 2941
2023
Q1 		$975K Sell
40,576
-370
-0.9% -$8.43K ﹤0.01% 2912
2022
Q4 		$798K Buy
40,946
+8,465
+26% +$167K ﹤0.01% 3032
2022
Q3 		$682K Sell
32,481
-221
-0.7% -$5.32K ﹤0.01% 3079
2022
Q2 		$636K Buy
32,702
+2,011
+7% +$47.4K ﹤0.01% 3214
2022
Q1 		$675K Sell
30,691
-17,066
-36% -$348K ﹤0.01% 3256
2021
Q4 		$762K Buy
47,757
+8,319
+21% +$129K ﹤0.01% 3204
2021
Q3 		$786K Sell
39,438
-7,890
-17% -$128K ﹤0.01% 3220
2021
Q2 		$818K Buy
47,328
+1,858
+4% +$33.3K ﹤0.01% 3214
2021
Q1 		$901K Buy
45,470
+505
+1% +$9.67K ﹤0.01% 3090
2020
Q4 		$785K Buy
44,965
+9,143
+26% +$180K ﹤0.01% 3042
2020
Q3 		$691K Buy
+35,822
New +$769K ﹤0.01% 2980

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Invesco's MIRM Position: Q2 2026 in Review

Invesco increased its Mirum Pharmaceuticals (MIRM) stake by 378% in Q2 2026, buying an estimated $108M and bringing the position to 1,364,084 shares worth $160M. The position accounts for 0.01% of the portfolio, ranked #759.

Invesco first reported a position in MIRM in Q3 2020 and has held it in 24 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Invesco held 1,364,084 shares of Mirum Pharmaceuticals worth $160M as of Q2 2026.
  • Invesco bought 1,078,848 Mirum Pharmaceuticals shares in Q2 2026, an estimated $108M.
  • Mirum Pharmaceuticals made up 0.01% of Invesco's portfolio in Q2 2026, its #759 holding.
  • Invesco first reported a position in Mirum Pharmaceuticals in Q3 2020 and has held it in 24 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.